Plasmatherapy has become empirically first-line treatment in atypical hemolytic uremic
syndrome (aHUS), although no prospective controlled trials have been conducted. Patients …

Background Mutations in complement factor H (CFH) are associated with complement
dysregulation and the development of an aggressive form of atypical hemolytic uremic …

The haemolytic uraemic syndrome (HUS) is characterized by the triad of thrombocytopenia,
microangiopathic haemolytic anaemia and acute renal failure. HUS may be classified as …

Factor H (FH) is a central complement regulator comprised of 20 short complement repeat
(SCR) domains. Nucleotide changes within this gene (CFH) have been observed in patients …

Mutations in complement factor H (HF1) gene have been reported in non-Shiga toxin-
associated and diarrhoea-negative haemolytic uraemic syndrome (D− HUS). We analysed …

The regulators of complement activation cluster at chromosome 1q32 contains the
complement factor H (CFH) and five complement factor H–related (CFHR) genes. This area …

Hemolytic uremic syndrome (HUS) is defined by the triad of mechanical hemolytic anemia,
thrombocytopenia and renal impairment. Atypical HUS (aHUS) defines non Shiga-toxin …

Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy associated
with mutations in complement proteins, most frequently in the main plasma alternative …

Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by the triad of
microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury. The …

Results Onset of aHUS occurred as frequently during adulthood (58.4%) as during
childhood (41.6%). The percentages of patients who developed the disease were 23 …